ARTICLE | Clinical News
Xalkori crizotinib: Phase III data
June 25, 2012 7:00 AM UTC
Top-line data from the open-label, international Phase III PROFILE 1007 trial in about 318 patients with previously treated ALK-positive advanced NSCLC showed that twice-daily 250 mg oral Xalkori met ...